By Research Area
Hot products 
-
Mouse Anti-BCL6 Recombinant Antibody (CBYY-0435) (CBMAB-0437-YY)
-
Mouse Anti-dsDNA Recombinant Antibody (22) (CBMAB-AP1954LY)
-
Mouse Anti-CEMIP Recombinant Antibody (3C12) (CBMAB-K0296-LY)
-
Mouse Anti-FeLV g27 Recombinant Antibody (1) (CBMAB-V208-1714-FY)
-
Rabbit Anti-ABL1 (Phosphorylated Y185) Recombinant Antibody (V2-443434) (PTM-CBMAB-0001YC)
-
Mouse Anti-CCT6A/B Recombinant Antibody (CBXC-0168) (CBMAB-C5570-CQ)
-
Mouse Anti-DLG1 Monolconal Antibody (4F3) (CBMAB-0225-CN)
-
Rabbit Anti-AKT3 Recombinant Antibody (V2-12567) (CBMAB-1057-CN)
-
Mouse Anti-ACTB Recombinant Antibody (V2-179553) (CBMAB-A0870-YC)
-
Mouse Anti-AKR1B1 Antibody (V2-2449) (CBMAB-1001CQ)
-
Mouse Anti-CCND2 Recombinant Antibody (DCS-3) (CBMAB-G1318-LY)
-
Mouse Anti-ENPP1 Recombinant Antibody (CBFYE-0159) (CBMAB-E0375-FY)
-
Mouse Anti-ACTN4 Recombinant Antibody (V2-6075) (CBMAB-0020CQ)
-
Mouse Anti-CASP8 Recombinant Antibody (CBYY-C0987) (CBMAB-C2424-YY)
-
Mouse Anti-F11R Recombinant Antibody (402) (CBMAB-0026-WJ)
-
Rabbit Anti-AP2M1 (Phosphorylated T156) Recombinant Antibody (D4F3) (PTM-CBMAB-0610LY)
-
Mouse Anti-FYN Recombinant Antibody (10) (CBMAB-S6332-CQ)
-
Mouse Anti-DDC Recombinant Antibody (8E8) (CBMAB-0992-YC)
-
Mouse Anti-FPR2 Recombinant Antibody (1D6) (CBMAB-F2628-CQ)
-
Rat Anti-CCR2 Recombinant Antibody (475301) (CBMAB-C1338-LY)
Lung Cancer Research
Lung cancer, formally known as primary bronchogenic carcinoma, originates from the epithelial cells of the bronchial mucosa or glands, which is one of the most prevalent malignancies worldwide. It is primarily classified into non-small cell lung cancer (NSCLC) and SCLC based on histopathological characteristics. While lung cancer is non-contagious, it exhibits significant familial clustering and genetic susceptibility. Common causes of lung cancer involve smoking, occupational exposure, and air pollution. According to the latest global cancer report released by the International Agency for Research on Cancer (IACR) in 2024, lung cancer ranks first in both new cases (12.4%) and deaths (18.7%), making it the leading cancer worldwide, particularly among men.
Discover our advanced antibody products, which will significantly enhance your work in lung cancer diagnosis and treatment research. These antibodies are carefully designed to possess high specificity and sensitivity, enabling accurate biomarker identification and assessment.
Please try the standard protocols which include: protocols, troubleshooting and guide.
Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme Linked Immunospot (ELISpot)
Proteogenomic
Other Protocols
Reference
- Lahiri, Aritraa, et al. "Lung cancer immunotherapy: progress, pitfalls, and promises." Molecular cancer 22.1 (2023): 40. Distributed under Open Access license CC BY 4.0. The image was modified by extracting and using only Part B of the original image.
Loading...
Compare
